Showing results (721-730 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|August 1, 2012
Markers for individualised therapy in endometrial carcinomaHelga B Salvesen, Ingfrid S Haldorsen, Jone Trovik
The Lancet. Oncology|June 26, 2012
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysisSashendra Senthi, Frank J Lagerwaard, Cornelis J A Haasbeek, et al.
The Lancet. Oncology|July 24, 2012
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialAndrea Necchi, Luigi Mariani, Nadia Zaffaroni, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
The Lancet. Oncology|June 29, 2012
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre studyQiujin Shen, Jia Fan, Xin-Rong Yang, et al.
The Lancet. Oncology|February 15, 2015
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trialAxel Le Cesne, Jean-Yves Blay, Julien Domont, et al.
The Lancet. Oncology|February 1, 2015
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trialIan H Kunkler, Linda J Williams, Wilma J L Jack, et al.
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in trials of cancer treatment: the past, present, and futureMichelle K Wilson, Katherine Karakasis, Amit M Oza
The Lancet. Oncology|February 22, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 studyLuis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, et al.
The Lancet. Oncology|March 13, 2022
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trialDavid Dearnaley, Victoria Hinder, Adham Hijab, et al.
Pageof 336